Table 3 Liver function-related parameters and serum lipids before and 12 weeks after consuming FRVE among men
Group (total = 10) | |||||||
|---|---|---|---|---|---|---|---|
Control (n = 5) | FRVE (n = 5) | ||||||
0 weeks | 12 weeks | pa | 0 weeks | 12 weeks | pa | pb | |
AST (IU/L)* | 22.40 (± 2.98) | 24.60 (± 4.40) | 0.273 | 25.80 (± 3.14) | 30.00 (±7.33) | 0.465 | |
△ change | 2.20 (± 2.44) | 4.20 (±4.35) | 0.834 | ||||
ALT (IU/L)* | 25.20 (± 6.93) | 26.20 (± 6.03) | 0.581 | 29.00 (± 2.66) | 28.80 (±6.11) | 0.684 | |
△ change | 1.00 (± 1.70) | −0.20 (±4.75) | 0.461 | ||||
AST/ALT ratio | 1.03 (± 0.14) | 0.99 (± 0.11) | 0.500 | 0.90 (± 0.09) | 1.02 (±0.04) | 0.225 | |
△ change | −0.04 (± 0.06) | 0.12 (±0.11) | 0.175 | ||||
GGT (mg/dL)* | 20.40 (± 3.04) | 20.60 (± 2.16) | 0.891 | 35.00 (± 10.89) | 27.60 (±7.81) | 0.068 | |
△ change | 0.20 (± 2.58) | −7.40 (±3.79) | 0.169 | ||||
ALP | 56.60 (± 3.57) | 56.00 (± 2.59) | 0.892 | 64.00 (± 4.16) | 62.40 (±3.44) | 0.461 | |
△ change | −0.60 (± 1.69) | −1.60 (±3.53) | 0.916 | ||||
TC (mg/dL) | 194.20 (± 12.87) | 191.60 (± 12.50) | 0.498 | 176.80 (± 11.32) | 169.40 (±15.50) | 0.225 | |
△ change | −2.60 (± 10.67) | −7.40 (±6.61) | 0.832 | ||||
TG (mg/dL)* | 152.20 (± 72.55) | 113.40 (± 24.49) | 0.893 | 275.40 (± 58.19) | 144.40 (±37.27) | 0.043 | |
△ change | −38.8 (± 50.50) | −131.0 (±43.32) | 0.076 | ||||
HDL-C (mg/dL) | 51.00 (± 3.82) | 56.20 (± 4.75) | 0.223 | 43.60 (± 5.56) | 47.60 (±3.47) | 0.138 | |
△ change | 5.20 (± 3.18) | 4.00 (±2.35) | 0.916 | ||||
LDL-C (mg/dL) | 112.76 (± 20.55) | 112.72 (± 12.61) | 0.893 | 78.12 (± 9.75) | 92.92 (±13.76) | 0.080 | |
△ change | −0.04 (± 10.47) | 14.80 (±7.19) | 0.175 | ||||